Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
26 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Avexa Limited - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Avexa Limited - Product Pipeline Review - 2014', provides an overview of the Avexa Limited's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Avexa Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Avexa Limited including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Avexa Limited's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Avexa Limited's pipeline products Reasons to buy - Evaluate Avexa Limited's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Avexa Limited in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Avexa Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Avexa Limited and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Avexa Limited - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Avexa Limited and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Avexa Limited Snapshot 4 Avexa Limited Overview 4 Key Information 4 Key Facts 4 Avexa Limited - Research and Development Overview 5 Key Therapeutic Areas 5 Avexa Limited - Pipeline Review 6 Pipeline Products by Stage of Development 6 Pipeline Products - Monotherapy 7 Pipeline Products - Out-Licensed Products 8 Out-Licensed Products/Combination Treatment Modalities 9 Avexa Limited - Pipeline Products Glance 10 Avexa Limited - Late Stage Pipeline Products 10 Phase III Products/Combination Treatment Modalities 10 Avexa Limited - Early Stage Pipeline Products 11 Preclinical Products/Combination Treatment Modalities 11 Discovery Products/Combination Treatment Modalities 12 Avexa Limited - Drug Profiles 13 apricitabine 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 Small Molecule to Inhibit HIV Integrase 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 AVX-15567 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Avexa Limited - Pipeline Analysis 17 Avexa Limited - Pipeline Products by Target 17 Avexa Limited - Pipeline Products by Route of Administration 18 Avexa Limited - Pipeline Products by Molecule Type 19 Avexa Limited - Pipeline Products by Mechanism of Action 20 Avexa Limited - Recent Pipeline Updates 21 Avexa Limited - Dormant Projects 22 Avexa Limited - Company Statement 23 Avexa Limited - Locations And Subsidiaries 24 Head Office 24 Other Locations & Subsidiaries 24 Appendix 25 Methodology 25 Coverage 25 Secondary Research 25 Primary Research 25 Expert Panel Validation 25 Contact Us 26 Disclaimer 26
List of Tables Avexa Limited, Key Information 4 Avexa Limited, Key Facts 4 Avexa Limited - Pipeline by Indication, 2014 5 Avexa Limited - Pipeline by Stage of Development, 2014 6 Avexa Limited - Monotherapy Products in Pipeline, 2014 7 Avexa Limited - Out-Licensed Products in Pipeline, 2014 8 Avexa Limited - Out-Licensed Products/ Combination Treatment Modalities, 2014 9 Avexa Limited - Phase III, 2014 10 Avexa Limited - Preclinical, 2014 11 Avexa Limited - Discovery, 2014 12 Avexa Limited - Pipeline by Target, 2014 17 Avexa Limited - Pipeline by Route of Administration, 2014 18 Avexa Limited - Pipeline by Molecule Type, 2014 19 Avexa Limited - Pipeline Products by Mechanism of Action, 2014 20 Avexa Limited - Recent Pipeline Updates, 2014 21 Avexa Limited - Dormant Developmental Projects,2014 22 Avexa Limited, Subsidiaries 24
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.